key: cord-0962633-22s1m08b
authors: Chen, TieLong; Dai, Zhe; Mo, Pingzheng; Li, Xinyu; Ma, Zhiyong; Song, Shihui; Chen, Xiaoping; Luo, Mingqi; Liang, Ke; Gao, Shicheng; Zhang, Yongxi; Deng, Liping; Xiong, Yong
title: Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study
date: 2020-04-11
journal: J Gerontol A Biol Sci Med Sci
DOI: 10.1093/gerona/glaa089
sha: f9a18334e2c1e7eca6cedf5ccd0abfbdfcaa8187
doc_id: 962633
cord_uid: 22s1m08b

BACKGROUND: In December 2019, the coronavirus disease 2019 (COVID-19) emerged in Wuhan city and spread rapidly throughout China and the world. In this study, we aimed to describe the clinical course and outcomes of older patients with COVID-19. METHODS: This is a retrospective investigation of hospitalized older patients with confirmed COVID-19 at Zhongnan Hospital of Wuhan University from January 1, 2020, to February 10, 2020. RESULTS: In total, 203 patients were diagnosed with COVID-19, with a median age of 54 years (interquartile range, 41-68; range, 20-91 years). Men accounted for 108 (53.2%) of the cases, and 55 patients (27.1%) were >65 years of age. Among patients who were 65 years and older, the mortality rate was 34.5% (19/55), which was significantly higher than that of younger patients at 4.7% (7/148). Common symptoms of older patients with COVID-19 included fever (94.5%; n=52), dry cough (69.1%; n=38), and chest distress (63.6%; n=35). Compared with young patients, older patients had more laboratory abnormalities and comorbidities. Through a multivariate analysis of the causes of death in older patients, we found that males, comorbidities, time from disease onset to hospitalization, abnormal kidney function, and elevated procalcitonin levels were all significantly associated with death. CONCLUSIONS: In the recent outbreak of COVID-19, our local hospital in Wuhan found that patients aged 65 and older had greater initial comorbidities, more severe symptoms, and were more likely to experience multi-organ involvement and death, as compared with younger patients.

In December 2019, a group of patients in Wuhan, China, were diagnosed with pneumonia of an unknown origin. The causative agent was discovered to be a novel coronavirus, known as 2019-nCoV [1] . Full-genome sequencing and phylogenic analysis indicated that 2019-nCoV is a distinct clade from the betacoronaviruses associated with human severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) [2] . The virus was subsequently renamed SARS-CoV-2, due to its similarity to the coronavirus responsible for severe acute respiratory syndrome (SARS-CoV).

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia is a newly recognized illness that initially spread from Wuhan (Hubei province) to other regions of China, before rapidly spreading around the world [3] [4] [5] [6] . The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern on March 11, 2020.

The clinical spectrum of COVID-19 ranges from mild to critical cases. Previous studies have focused on general epidemiological findings, clinical presentations, and clinical outcomes of patients of COVID-19 [7] [8] [9] [10] [11] . However, the specific information about older patients remains unknown.

While several drugs and vaccines are under investigation, there are no effective therapies or vaccines currently available for COVID-19. The objectives of this clinical case study were to: (1) describe the clinical characteristics of 203 discharged patients with COVID-19, (2) compare the clinical characteristics of older and young patients, and (3) assess the relevant factors that may affect the prognosis of patients with COVID-19. The findings from this study will improve the awareness of COVID-19 pneumonia and may help enhance patient care in the future.

A c c e p t e d M a n u s c r i p t 5 COVID-19 was defined according to the diagnostic and treatment guidelines for SARS-CoV-2 issued by the Chinese National Health Committee version 3-6. Severe COVID-19 was designated as having one of the following criteria: (a) respiratory distress with respiratory frequency ≥30/min; (b) pulse oximeter oxygen saturation ≤93% at rest; and (c) oxygenation index (artery partial pressure of oxygen/inspired oxygen fraction, PaO 2 / FiO 2 ) ≤300 mm Hg.

Acute respiratory distress syndrome (ARDS) was defined according to the Berlin definition [13] . Cardiac injury was defined by serum levels of cardiac biomarkers, such as troponin I, rising above the 99 th percentile upper reference limit or the presence of new electrocardiography and echocardiography abnormalities. Acute kidney injury was identified according to the "Kidney Disease: Improving Global Outcomes" definition. The duration from disease onset to hospital admission, dyspnea, ARDS, intensive care unit (ICU) admission, and discharge were also recorded.

Sputum and throat swab specimens were collected from all patients upon admission and tested by real-time polymerase chain reaction (RT-PCR) for SARS-CoV-2 RNA within 3 h. A c c e p t e d M a n u s c r i p t 6 days, or when their resting respiratory rate was >30 per min, oxygen saturation was <93% without oxygen, or multiple pulmonary lobes showed more than 50% progression of disease within 48 h of imaging. Patients also received treatment with probiotics in most cases.

Quinolones and second-generation beta-lactams (oral and intravenous) were administered if fever lasted longer than seven days or C-reactive protein levels were >20 mg/L (normal range 0-10 mg/L). Patients suspected of having SARS-CoV-2 were discharged from hospital once the results of two RT-PCR tests, taken 24 h apart, were negative for SARS-CoV-2.

Categorical variables were described as frequency rates and percentages, and continuous variables were described using mean, median, and interquartile range (IQR) values. Means for continuous variables were compared using independent group t-tests when the data were normally distributed. In other instances, the Mann-Whitney test was used. Data (non-normal distribution) from repeated measures were compared using the generalized linear mixed model. Proportions for categorical variables were compared using the χ 2 test, although the Fisher exact test was used when the data were limited. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 16.0 software (SPSS Inc., Chicago, IL USA). For unadjusted comparisons, a two-sided α of less than 0.05 was considered statistically significant. The analyses have not been adjusted for multiple comparisons and, given the potential for type I error, the findings should be interpreted as exploratory and descriptive.

Univariate and stepwise multivariate logistic regression models were used to analyze all variables as potential predictors for the death of older patients. All variables with a pvalue of less than 0.10 in the univariate logistic regression models were included in the A c c e p t e d M a n u s c r i p t 7 multivariate logistic regression model. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for each covariate.

The demographic and clinical characteristics are shown in Table 1 ). In addition, older patients displayed higher rates of chest tightness, shortness of breath, and dyspnea when admitted to our hospital. Approximately 87.3% of older patients admitted to the hospital were severely or critically ill, which was significantly higher that of younger patients (39.9%). Table 2 shows the laboratory and radiologic findings of the patients upon admission to the hospital. Of 203 patients who underwent chest CT upon admission, 172 (84.7%) patients showed bilateral lung involvement on chest radiographs ( Table 2) . Typical chest CT findings of infected patients during admission included bilateral or multiple lobular or subsegmental areas of consolidation or bilateral ground-glass opacity (Figure 1) . Twenty-one patients A c c e p t e d M a n u s c r i p t 8 (10.3%) had pleural effusion (Figure 2) . On average, a five-day follow-up CT scan revealed progression in 48 patients (23.6%). Compared with patients less than 65 years of age, the proportion of older patients who underwent CT imaging upon admission showed double lung disease, combined pleural effusion, and higher rates of CT re-examination (all P<0.05).

Various therapies, including oxygen therapy, mechanical ventilation, expectorant, antiviral treatment, and corticosteroid therapy were initiated in 60.6%, 19.2%, 32.5%, 62.9%, and 52.7% of patients, respectively. The percentages of older patients using oxygen therapy, mechanical ventilation, and expectorant were significantly higher than those of the younger patients ( Table 3) . Of the 203 patients, the mortality rate was 12.8% with 26 deaths. The other patients improved and were discharged from the hospital. The mortality of older patients was significantly higher than that of younger patients (34.5% vs. 4.7%, P<0.001).

The primary cause of death was ARDS or ARDS with multiple organ damage ( Table 3) .

Nine significant factors in the univariate analysis were put into the multivariate analysis to identify independent factors associated with the death of older patients (Table 4) . Men, those with multiple comorbid health conditions, dyspnea, elevated creatinine, aspartate aminotransferase, and procalcitonin had a much higher risk of death.

Human coronavirus is one of the primary pathogens of respiratory infections worldwide. The This study found that the proportion of older patients with chest tightness, shortness of breath, dyspnea, and abdominal pain was significantly higher than that of younger patients during hospital admission. As these symptoms may be associated with poorer prognoses, physicians should monitor older patients for these symptoms. Our hospital previously reported that high infection rates of medical staff and hospitalized patients [10]. These older patients often have chronic and comorbid conditions that can negatively affect overall outcomes. The incubation period before fever may permit greater spread of the virus. Therefore, during epidemics involving new respiratory diseases, physicians should take A c c e p t e d M a n u s c r i p t 10 precautions to minimize exposure, increase the utility of medical imaging, and viral nucleic acid diagnostics, in order to improve early diagnosis and prevent disease.

The mortality of SARS-CoV has been reported as more than 10%, while MERS-CoV has been reported to be higher than 35% [15] . In the current study, there were 26 deaths out of 203 patients, suggesting that the total mortality was 12.8%, which resembles that of a previous study [9] . The remaining patients improved and were discharged from the hospital.

However, the mortality rate of older patients was significantly higher, at 34.5% (19/55). This rate was significantly higher than that of young people and previously reported patients with COVID-19, but lower than the mortality rate of 61.5% (32/52) in ICU patients reported by Xiaobo Yangasp et al. [11] . This is consistent with previous studies reporting that older patients have poorer prognostic factors and are more likely to experience critical disease [7, 11] , suggesting that older patients should seek early screening and early diagnosis to reduce the mortality rates associated with COVID-19.

Studies on ICU patients with COVID-19 suggest that the older [8, 11], male patients, and complications are all risk factors for death and disease severity associated with COVID-19.

The proportion of cardiovascular disease, cerebrovascular disease, COPD, and tumors in older patients was significantly higher than those of younger patients, which is consistent with studies mentioned above and indicates that comorbidities may be factors in the high mortality rates of older patients.

The proportion of older patients with severe and critical illness was also significantly higher than that of younger patients, and the time from disease onset to the admission of older patients was longer than that of younger patients. Previous studies have suggested that patients with aggravations often have an exacerbation in within one week of disease onset, including dyspnea [7, 10] . Hence, monitoring and supportive treatments should be strengthened around this time.

A c c e p t e d M a n u s c r i p t 11 Similar to previous studies, important laboratory findings overall included low lymphocyte counts and albumin, elevated erythrocyte sedimentation, LDH, D-dimer, IL-6, and CRP with predominantly bilateral lung disease on CT scan [14] . As compared with younger patients, older patients had higher percentages with elevated white blood cells and procalcitonin, lower lymphocyte counts, higher percentages of liver and kidney dysfunction, higher LDH, and higher fasting blood glucose. The proportion with elevated D-dimer, ESR, CRP, and IL-6 all increased significantly, as compared with younger patients. In addition, older patients may be more prone to bacterial infections, liver and kidney dysfunction, and changes in blood glucose and coagulation levels.

Until now, no specific treatments have been recommended for COVID-19 infection, except for meticulous supportive care. The treatments currently available include symptomatic comprehensive supportive therapies, such as oxygen therapy, expectorants, prevention and treatment of infections, antivirals, and immune regulators. This study found that the proportion of older patients requiring oxygen therapy, expectoration, mechanical ventilation, or transfers to the ICU was significantly higher than that of younger patients, similar to previous studies. As older patients are more likely to have comorbidities and reduced lung function, these may be negative factors that can affect the severity of COVID- Further multivariate analysis of the influencing factors of death in older patients with COVID-19 pneumonia shows that males and those with any complications, elevated creatinine, and elevated procalcitonin levels were associated with death. Another interesting finding is that the time between onset and hospitalization of the older patients who died was significantly shorter than patients who survived, which was also true in the multivariate analysis. Previous studies [10, 11] reported that the time from symptoms to dyspnea and ICU transfer were between 7 days and 9 days, respectively. It has been speculated that patients with shorter symptom duration may have a more rapid progression of the disease. The exact reason needs to be further explored by further studies with larger patient populations. The effects of gender on the progression of the disease have not been consistently reported. This study suggests being a is an unfavorable factor in older patients, but the effects of gender reported in patients from different ICUs have not been consistent.

This study has several limitations. First, due to the concentrated outbreak of a large number of patients in the early stage of the pandemic, some personal histories were incomplete. This study did not include smoking history, which may also be an important risk factor for infection and death in older patients. Respiratory tract specimens were used for diagnosis using RT-PCR. Due to the shortage of reagents, most early studies did not use dynamic virologic examination as an observation index for clinical prognosis evaluation. In this study, virologic quantification was used as an index to assess disease progression. In addition, our institution was only the specified hospital for severe patients during the early outbreak, which could have resulted in some selection bias. 

In short, this single-center retrospective study suggests that older patients, who are more likely to present with chronic comorbidities, have a high mortality rate of 34.5%. Through a multivariate analysis of the causes of death in older patients, we found that males, comorbidities, time from disease onset to hospitalization, abnormal kidney function, and elevated procalcitonin levels were all significantly associated with death. A c c e p t e d M a n u s c r i p t 26 

A Novel Coronavirus from Patients with Pneumonia in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

First Case of 2019 Novel Coronavirus in the United States

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Potential Presymptomatic Transmission of SARS-CoV-2

A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period

Clinical features of patients infected with

M a n u s c r i p t A c c e p t e d M a n u s c r i p t